SOURCE: Plandai Biotechnology, Inc.
NEW YORK, NY--(Marketwired - Apr 30, 2014) - Plandaí Biotechnology (OTCQB: PLPL) has been given the go-ahead to conduct human clinical trials in a 3-month study that will compare the oral bioavailability in the company's Phytofare™ Catechin Complex to green tea extracts. In this study, to be conducted at the North West University in Potchefstroom, South Africa, Plandaí's 2 technologies, hydrodynamic sheering and Pheroid® entrapment, will be put to the test versus a product that hasn't undergone these processes.
For investors, this is a development that should lead to Plandaí making its mark in the extracts industry as the company that delivers products higher in bioavailability.
Currently the recruitment process is underway to find the people who will take part in this study due to commence in mid-May. Plandaí stated in a recent press release that the clinical trial will compare the oral bioavailability (the level of catechin absorption into the blood stream) of Phytofare™ compared with green tea extracts that have not undergone the company's proprietary hydrodynamic sheering process which rearranges the isomeric configuration of the molecules into a format biocompatible with human tissues, or extracts that have not been further entrapped in Pheroid® like the company's Phytofare™ extracts.
It's Plandaí's belief that the trial will demonstrate that Phytofare™ and Phytofare™ entrapped in Pheroid® have materially significant superior bioavailability, which should provide the ability to deliver a clinical level of plant nutrients at relatively low dosages. The company believes that this will unlock the health potential of not only green tea but also other phytonutrients which suffer from low natural bioavailability.
Plandaí's CEO Roger Duffield said of the clinical trials, "At Plandaí, we believe that nature has provided us with most of what we need to combat everything from obesity to cancer to Alzheimer's, we just need to improve our bodies' ability to process these nutrients. Phytofare™ will hopefully achieve that very thing."
The company says the final results from what will be a "three leg" clinical trial should be available in July 2014. Plandaí's clinical trials represent more of what has been exhaustive research and testing on the company's Phytofare™ brand. The Phytofare™ Catechin Complex will be the first product to market for Plandaí, which includes the entire catechin profile derived from live green tea that is grown and processed on the Company's 8,000 acre Senteeko estate in South Africa.
About Stock Market Media Group
SMMG is a Research and Content Development IR firm that offers a platform for corporate stories to unfold in the media with Reports, Interviews and Articles. SMMG is compensated for Plandaí articles, reports and interviews by a third party who reserves the right to buy, sell or remain neutral on securities at any time before, during, or after the publication of this article. To date, SMMG has received total compensation of $44,390, for content related to Plandaí. For more information: www.stockmarketmediagroup.com/.